Contents
Contents
In the Aqua Pharmaceuticals kickback settlement, Almirall, formerly Aqua, agreed to pay $3.5 million over alleged kickbacks to dermatology prescribers. The company allegedly used meals, gifts and paid professional roles to buy prescriptions for its skin treatments. A former sales representative’s complaint showed what those arrangements could look like inside the business: a speaker paid without delivering educational material, meals delivered to a provider’s home, and gift cards management had told employees to buy.
The Justice Department announced the settlement on May 29, 2019, covering alleged conduct from 2012 through 2017. Almirall separately agreed to a $3.1 million resolution of similar allegations with California’s Department of Insurance, which conducted its own investigation. The former Aqua sales representative brought the federal False Claims Act case.
The government alleged that Aqua bought influence over prescribing through both personal benefits and payments for professional services. Its announcement listed in-office and out-of-office meals and food, entertainment, trips, gift cards and gifts. It also described speaking engagements, advisory boards and consulting services for which inducing Aqua prescriptions was one purpose of the compensation.
The whistleblower’s complaint described Aqua’s dependence on dermatologists and physician assistants choosing its products over competitors’ products. The whistleblower’s own work included detailing Cordran and Xolegel, followed by promoting Acticlate after its launch.
The complaint alleged that prescriptions induced by these payments led to claims paid by government health care programs. In announcing the settlement, the Justice Department specifically named Medicare and Tricare. Patients depended on the prescriber’s medical judgment. A company paying to influence that judgment could also take business from competitors selling on the merits of their drugs.
The complaint described an Aqua speaker event in Philadelphia in March 2014. According to the whistleblower, the people present were the physician, a sales representative and Aqua’s national sales director.
The complaint put the missing work beside the payment:
Even though no other healthcare professional attended the dinner, and he did not discuss or present any educational materials, [the speaker] was still paid a substantial honorarium.
Whistleblower’s allegation, United States ex rel. John Doe v. Aqua Pharmaceuticals, LLC et al., complaint, paragraph 84
The whistleblower then alleged that Aqua paid approximately $700 to 800 for an expensive dinner for the three of them. The complaint described the purpose as keeping the physician writing Aqua prescriptions. In that account, the educational work disappeared and the compensation survived.
The same separation appeared in Novartis’s 2020 speaker-program settlement. Novartis admitted paying doctors honoraria for events that never took place. It also admitted that a sales representative arranged fake restaurant receipts and used the budgeted money to buy gift cards for high-prescribing doctors.
The Aqua complaint traced gift cards back to management instructions. During the dinner, the sales director allegedly asked the representative whether he bought gift cards for his accounts. The representative said he did. The director told him to stop, but also said he was not in trouble because management had previously directed him to buy them.
The alleged gifts had management approval. The decision sat above the person submitting the expense.
The complaint also alleged that two physician assistants at a dermatology practice asked for gift cards and meals for their families, including meals on days they were not working. Both held Aqua advisor roles. When the whistleblower asked her manager whether the requests were appropriate, he allegedly told her the practice was approved and she should comply.
The benefits reached beyond the office. According to the complaint, Aqua paid to cater a family christening at a provider’s home. Management allegedly permitted the representative to pay on Friday for delivery over the weekend to conceal the private meal. The whistleblower said she retained receipts for meals delivered to the home.
The whistleblower alleged that Aqua reimbursed these expenses without requiring itemized receipts or attendee lists. Instead, representatives submitted a total on an expense report and were told to avoid an even number. Her manager allegedly reviewed and approved the payments and reports.
The complaint went further: after Almirall purchased Aqua, management allegedly instructed representatives and managers to revise prior expense reports and invent or rewrite attendance lists for earlier speaking events.
The complaint said Aqua circulated new promotional guidelines in April 2014 prohibiting gift cards and office lunches. Later, a provider allegedly texted the whistleblower asking her to resume gift cards or find another way to provide benefits. When the request reached her manager, he allegedly asked what she could do to help the provider.
The complaint alleged a continuing system of advisor payments, including honoraria for meals and travel and separate payments for surveys. It described how those arrangements sat within the sales territories:
Each Aqua sales territory has its own advisors and speakers. Similar to Relator’s territory, these advisors receive honorariums for lunches, dinners, and traveling to advisory meetings, and separate monthly honorariums for completing surveys.
Whistleblower’s allegation, United States ex rel. John Doe v. Aqua Pharmaceuticals, LLC et al., complaint, paragraph 107
An advisor relationship could therefore generate payments for different activities over time. The government’s allegation reached consulting as well as speaking: inducing prescriptions was one purpose of the compensation.
Sales personnel may know why a provider became an advisor. People administering the program may know whether the meeting happened, what the survey produced and how the fee was approved. We connect those accounts to the payments and the prescribing business the arrangement was intended to influence.
On the receiving side of the alleged prescribing incentives, a physician assistant agreed to a $25,000 civil settlement over allegations that she solicited and received benefits intended in part to induce Aqua prescriptions. The Justice Department announced that recipient-side resolution on July 10, 2020.
The alleged benefits included meals, gift cards, gifts and paid speaking, advisory or consulting arrangements.
Aqua’s alleged sales incentives reached physician assistants as well as physicians. Someone inside a dermatology practice may see the requests for benefits, the deliveries and the paid advisor relationship from the receiving side. That view can explain a transaction that a manufacturer expense report describes only as a meal or professional fee.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. In Aqua’s case, the Justice Department announced a share of the recovery for the former sales representative who brought the case.
Her position gave her access to the account relationships, requests and management decisions behind the payments. The complaint drew on that firsthand work, including benefits she had been instructed to provide. For pharmaceutical whistleblowers, knowledge of how an expense came to be approved can matter as much as the ledger entry itself.
The Aqua allegations connect the event, the benefit and the decision to pay. Each payment had a stated purpose and a reality behind it.
Those connections are where our whistleblower experts focus. A sales representative, program administrator or practice employee may hold the part of the story that explains why the official description of a payment is incomplete. We work with that person to connect the commercial purpose, management decisions and resulting prescription claims into a pharmaceutical fraud case.
If you saw speaker fees without a presentation, family meals charged to a sales budget or advisor payments driven by prescribing, speak with our whistleblower experts about the payments you saw. We build the case with you and bring in pharmaceutical kickback whistleblower lawyers who understand prescriber payments and government drug claims. We stay beside you throughout, turning your knowledge of the sales practices into your strongest pharmaceutical whistleblower case.